Shopping Cart
Remove All
Your shopping cart is currently empty
Cosibelimab
(Synonyms: TG-1501, TG 1501, CK-301, CK 301) Copy Product Info
🥰Excellent
Synonyms: TG-1501, TG 1501, CK-301, CK 301
Catalog No. T77151 Copy Product Info
Purity: 95%
🥰Excellent
Cosibelimab (CK-301; TG-1501) is a fully human, high-affinity monoclonal antibody that inhibits PD-L1 by preventing interaction between PD-L1 and PD-1. Cosibelimab (CK-301; TG-1501), which contains a functional Fc domain, effectively induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against PD-L1-positive cell lines, including lymphoma cells. Cosibelimab (CK-301; TG-1501) is therefore valuable for immuno-oncology investigations involving immune checkpoint signaling, Fc-mediated immune effector functions, and tumor immune microenvironment regulation.
Cas No. 2216751-26-5
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | - | In Stock | |
| 5 mg | $647 | - | In Stock | |
| 10 mg | $987 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:98.4% (SDS-PAGE); 96.1% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Cosibelimab (CK-301; TG-1501) is a fully human, high-affinity monoclonal antibody that inhibits PD-L1 by preventing interaction between PD-L1 and PD-1. Cosibelimab (CK-301; TG-1501), which contains a functional Fc domain, effectively induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against PD-L1-positive cell lines, including lymphoma cells. Cosibelimab (CK-301; TG-1501) is therefore valuable for immuno-oncology investigations involving immune checkpoint signaling, Fc-mediated immune effector functions, and tumor immune microenvironment regulation. |
| In vitro | Cosibelimab exhibits a functional Fc region capable of inducing antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity, thereby mediating tumor cell killing by effector cells such as natural killer cells[1]. Cosibelimab blocks the interaction between PD-L1 and PD-1 or B7-1 receptors, reactivates T cells, restores adaptive immunity, and activates innate immunity[1]. |
| Synonyms | TG-1501, TG 1501, CK-301, CK 301 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | PD-L1 |
| Cas No. | 2216751-26-5 |
| Isotype | Human IgG1 lambda2 |
| Recommended Isotype Control |
| Storage | Store at low temperature, -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: Cosibelimab chemical structure | Cosibelimab in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.